IDEXX Laboratories Stock Price, News & Analysis

IDEXX Laboratories (NASDAQ: IDXX) has announced the launch of IDEXX Cancer Dx™, a groundbreaking diagnostic panel for early detection of lymphoma in dogs. The affordable blood test, priced as low as $15, can be integrated into annual wellness screenings and provides results within 2-3 days.

The test targets the significant market of 20 million dogs at higher risk for cancer in North America, addressing a critical need as 1 in 4 dogs in the U.S. are expected to receive a cancer diagnosis in their lifetime. Lymphoma specifically accounts for nearly 25% of new canine cancer diagnoses.

The panel features high accuracy, simple workflow integration, and includes access to IDEXX Medical Consultants. The test can detect lymphoma before clinical signs appear and will provide B-cell and T-cell phenotype classification for positive results at no additional cost. The service will be available in the U.S. and Canada in late March 2025, with plans to expand the panel over the next three years to cover the majority of canine cancer cases.

IDEXX Laboratories (NASDAQ: IDXX), a global pet healthcare innovation leader, has announced it will release its 2024 fourth quarter and full year financial results on Monday, February 3, 2025, before market opening. The company will host an analyst conference call at 8:30 a.m. ET on the same day.

Investors can access the live webcast, prepared remarks transcript, and Q4 2024 Earnings Snapshot through the company's investor relations website. The webcast recording will be available after 1:00 p.m. ET and remain accessible for one year. For telephone access, participants can dial 1-800-289-0462 or 1-323-794-2442 using passcode 803218.

IDEXX Laboratories (NASDAQ: IDXX) has announced an expansion of its share repurchase program. The company's Board of Directors has authorized the repurchase of 5 million additional shares of common stock, supplementing the existing 1.3 million shares remaining under previous authorizations as of December 3, 2024.

The repurchases can be executed through open market operations, including Rule 10b5-1 plans, or through negotiated transactions at management's discretion. The program has no specified end date and can be suspended or discontinued at any time.

IDEXX Laboratories (NASDAQ: IDXX) announced a planned CFO transition. Brian McKeon will retire effective June 1, 2025, with Andrew Emerson, current Senior VP of Corporate and CAG Finance, succeeding him as Executive VP, CFO, and Treasurer on March 1, 2025. McKeon will serve as EVP and Special Advisor until his retirement to ensure a smooth transition. Emerson brings nearly 20 years of financial experience and 9 years at IDEXX, having overseen CAG finance since 2015, which generates over 90% of IDEXX's total revenue. The company reaffirmed its 2024 full year guidance as provided on October 31, 2024.

IDEXX Laboratories reported Q3 2024 results with revenue of $976 million, showing 7% reported growth and 6% organic growth. The Companion Animal Group (CAG) segment grew 7% reported and 6% organic, while Water revenue increased 13%. Earnings per share reached $2.80, up 11% reported and 12% comparable, with operating margin expansion of 110 basis points. The company adjusted its 2024 revenue guidance to $3,865-$3,890 million, reducing previous estimates by ~1% due to macro conditions affecting U.S. veterinary clinic visits. The updated EPS outlook is narrowed to $10.37-$10.53, maintaining consistent midpoint compared to prior guidance.

IDEXX Laboratories reported strong Q3 2024 results with 7% revenue growth reaching $976 million. The company achieved 6% organic growth, driven by Companion Animal Group (CAG) performance and Water revenue growth of 13%. Earnings per share reached $2.80, up 11% as reported.

The company adjusted its 2024 revenue guidance to $3,865-$3,890 million, a reduction of $38 million, reflecting near-term impacts on growth from macro conditions affecting U.S. veterinary clinic visits. The updated EPS outlook range is $10.37-$10.53, maintaining consistent projections supported by solid operating margin performance and benefits from lower projected interest expense.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced the upcoming release of its 2024 third quarter financial results. The results will be made public on Thursday, October 31, 2024, before the market opens. Following the release, the company will host an analyst conference call at 8:30 a.m. EDT on the same day.

Investors and interested parties can access a live webcast of the conference call, along with a transcript of prepared remarks and the Q3 2024 Earnings Snapshot, through the IDEXX website at www.idexx.com/investors. An archived version of the webcast will be available after 1:00 p.m. ET and remain accessible for one year. For those preferring to listen via telephone, the call can be accessed by dialing 1-800-289-0462 or 1-323-794-2442 and using the passcode 205740.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Jay Mazelsky, along with Executive VP and CFO, Brian McKeon, will engage in a fireside chat on Wednesday, September 4, 2024, from 11:30 am to 12:05 pm (EDT).

Investors and interested parties can access a live audio webcast of the presentation through the IDEXX website at www.idexx.com/investors. For those unable to attend the live event, an archived version of the presentation will also be made available through the same link.

IDEXX Laboratories (NASDAQ: IDXX) reported Q2 2024 results with revenue of $1,004 million, a 6% increase as reported and 7% organic growth. Companion Animal Group (CAG) revenue grew 6% as reported and 7% organic, while Water revenue increased 9% as reported and 10% organic. CAG Diagnostics recurring revenue grew 6% as reported and 7% organic. EPS was $2.44, down 9% as reported but up 15% on a comparable basis, excluding a $0.56 per share impact from a litigation expense accrual.

The company updated its 2024 guidance, projecting revenue of $3,885 - $3,945 million (6.2% - 7.8% growth) and EPS of $10.31 - $10.59. The EPS outlook was reduced by $0.56 at midpoint due to the litigation expense accrual. IDEXX maintains a strong position in pet healthcare innovation, with record Q2 premium instrument placements and 11% annual growth in its global premium instrument installed base.